Inhibition of the aspartic proteinase from HIV-2

Area of Science:

• Biochemistry
• Virology
• Drug Discovery

Background:

• The human immunodeficiency virus type 2 (HIV-2) aspartic proteinase is a key target for antiviral therapies.
• Understanding the enzyme's kinetics and inhibitor interactions is crucial for developing effective treatments.
• Previous studies have characterized the proteinase from HIV-1, providing a basis for comparison.

Purpose of the Study:

• To determine the kinetic constants for the interaction of HIV-2 aspartic proteinase with a synthetic substrate.
• To evaluate the efficacy of various inhibitors against HIV-2 aspartic proteinase at different pH values.
• To compare the inhibitory profiles of HIV-2 and HIV-1 aspartic proteinases.

Main Methods:

• Enzyme kinetics assays were performed using a synthetic substrate.
• The activity of HIV-2 aspartic proteinase was measured in the presence of different inhibitors (acetyl-pepstatin and H-261) across a range of pH values.
• Kinetic constants were calculated based on enzyme activity measurements.

Main Results:

• Kinetic constants for HIV-2 aspartic proteinase interacting with a synthetic substrate were determined.
• Acetyl-pepstatin demonstrated higher efficacy against HIV-2 aspartic proteinase compared to the renin inhibitor H-261.
• This observed inhibitory effect was contrary to the results previously reported for the HIV-1 aspartic proteinase.

Conclusions:

• The study elucidates the kinetic properties of HIV-2 aspartic proteinase.
• Differential inhibitor efficacy suggests distinct active site characteristics between HIV-1 and HIV-2 proteinases.
• Findings provide valuable insights for the design of targeted antiviral agents against HIV-2.